, Société de pathologie infectieuse de langue française, 2009.

, Consensus conference on bacterial meningitis

, Med Mal Infect, vol.39, pp.175-186

D. Van-de-beek, C. Cabellos, O. Dzupova, S. Esposito, M. Klein et al., , p.374

B. Mourvillier, C. Ostergaard, P. Pagliano, H. W. Pfister, R. C. Read et al., , p.375

, ESCMID Study Group for Infections of the Brain (ESGIB). 2016. ESCMID guideline: 376 diagnosis and treatment of acute bacterial meningitis, Clin Microbiol Infect, vol.22, pp.37-62

A. R. Tunkel, B. J. Hartman, S. L. Kaplan, B. A. Kaufman, K. L. Roos et al., Practice guidelines for the management of bacterial meningitis, Clin Infect Dis, vol.379, pp.1267-1284, 2004.

N. Simon, B. Dussol, E. Sampol, R. Purgus, P. Brunet et al., , vol.382

, Population pharmacokinetics of ceftriaxone and pharmacodynamic 383 considerations in haemodialysed patients, Clin Pharmacokinet, vol.45, pp.493-501, 2006.

S. Iida, T. Kawanishi, and M. Hayashi, Indications for a ceftriaxone dosing regimen in 385, 2011.

, Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis 386 and simulation, J Pharm Pharmacol, vol.63, pp.65-72

S. Iida, H. Kinoshita, T. Kawanishi, and M. Hayashi, The pharmacokinetics of ceftriaxone 388 based on population pharmacokinetics and the prediction of efficacy, 2009.

, Eur J Drug Metab Pharmacokinet, vol.34, pp.107-115

D. Garot, R. Respaud, P. Lanotte, N. Simon, E. Mercier et al., , p.391

L. Guellec and C. , Population pharmacokinetics of ceftriaxone in critically ill septic 392 patients: a reappraisal, Br J Clin Pharmacol, vol.72, pp.758-767, 2011.

T. P. Lodise, R. Nau, M. Kinzig, R. N. Jones, G. L. Drusano et al., Comparison of the 394 probability of target attainment between ceftriaxone and cefepime in the cerebrospinal 395 fluid and serum against Streptococcus pneumoniae, Diagn Microbiol Infect Dis, vol.58, p.445, 2007.

A. Lautrette, T. Phan, L. Ouchchane, A. Aithssain, V. Tixier et al., High creatinine clearance in critically ill patients with community-acquired acute 399 infectious meningitis, BMC Nephrol, vol.398, p.124, 2012.

M. Whitby and R. Finch, Bacterial meningitis. Rational selection and use of antibacterial 401 drugs, Drugs, vol.31, pp.266-278, 1986.

L. Turnier, P. Navas, D. Garot, D. Guimard, T. Bernard et al., , p.403

J. Hoff, A. Chiffoleau, M. Dary, L. Leclair-visonneau, M. Grégoire et al., , p.404

V. Sébille, E. Dailly, and N. Asseray, Tolerability of high-dose ceftriaxone in CNS infections: a 405 prospective multicentre cohort study, J Antimicrob Chemother, vol.74, pp.1078-1085

M. Verdier, O. Tribut, P. Tattevin, L. Tulzo, Y. Michelet et al., , p.407, 2011.

, Simultaneous determination of 12 beta-lactam antibiotics in human plasma by high-408 performance liquid chromatography with UV detection: application to therapeutic drug 409 monitoring, Antimicrob Agents Chemother, vol.55, pp.4873-4879

S. E. Briscoe, B. C. Mcwhinney, J. Lipman, J. A. Roberts, and J. Ungerer, A method for 411 determining the free (unbound) concentration of ten beta-lactam antibiotics in human 412 plasma using high performance liquid chromatography with ultraviolet detection, J 413 Chromatogr B, vol.907, pp.178-184, 2012.

M. N. Neely, M. G. Van-guilder, W. M. Yamada, A. Schumitzky, and R. W. Jelliffe, Accurate 415 detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric 416 pharmacometric modeling and simulation package for R, Ther Drug Monit, vol.34, pp.467-476, 2012.

M. Bergstrand, A. C. Hooker, J. E. Wallin, and M. O. Karlsson, Prediction-corrected visual 418 predictive checks for diagnosing nonlinear mixed-effects models, AAPS J, vol.13, pp.143-151, 2011.

J. A. Roberts, S. K. Paul, M. Akova, M. Bassetti, J. J. De-waele et al., , p.420

D. Koulenti, C. Martin, P. Montravers, J. Rello, A. Rhodes et al.,

. Dali-study, DALI: defining antibiotic levels in intensive care unit patients: are 422 current ?-lactam antibiotic doses sufficient for critically ill patients?, Clin Infect Dis, vol.423, pp.1072-1083, 2014.

. Société-française-d'anesthésie and . De-réanimation, Optimisation du traitement par 425 bêta-lactamines, 2018.

. Eucast, MIC and zone distributions and ECOFFs, 2019.

K. Stoeckel, P. J. Mcnamara, R. Brandt, H. Plozza-nottebrock, and W. H. Ziegler, Effects of 430 concentration-dependent plasma protein binding on ceftriaxone kinetics, Clin Pharmacol 431 Ther, vol.29, pp.650-657, 1981.

J. C. Bos, J. M. Prins, M. C. Mistício, G. Nunguiane, C. N. Lang et al., , p.433

R. M. Hest, Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone 434 in adult severely ill sub-Saharan African patients: a population pharmacokinetic 435 modelling study, J Antimicrob Chemother, vol.73, pp.1620-1629, 2018.

M. Schleibinger, C. L. Steinbach, C. Töpper, A. Kratzer, U. Liebchen et al., , p.437

M. G. Kees, Protein binding characteristics and pharmacokinetics of ceftriaxone in 438 intensive care unit patients, Br J Clin Pharmacol, vol.80, pp.525-533, 2015.

G. Heinemeyer, J. Link, W. Weber, V. Meschede, and I. Roots, Clearance of ceftriaxone in 440 critical care patients with acute renal failure, Intensive Care Med, vol.16, pp.448-453, 1990.

V. D. Sharma, A. Singla, M. Chaudhary, and M. Taneja, Population Pharmacokinetics, p.442, 2016.

, Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects

, AAPS PharmSciTech, vol.17, pp.1192-1203

J. A. Roberts, F. Pea, and J. Lipman, The clinical relevance of plasma protein binding 445 changes, Clin Pharmacokinet, vol.52, pp.1-8, 2013.

D. Tsai, P. Stewart, R. Goud, S. Gourley, S. Hewagama et al., , p.447

J. Lipman and J. A. Roberts, Total and unbound ceftriaxone pharmacokinetics in critically 448 21, 2016.

, ill Australian Indigenous patients with severe sepsis, Int J Antimicrob Agents, vol.48, pp.748-449

R. Nau, H. W. Prange, P. Muth, G. Mahr, S. Menck et al., Passage of 451 cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges, 1993.

, Antimicrob Agents Chemother, vol.37, pp.1518-1524

R. Latif and A. S. Dajani, Ceftriaxone diffusion into cerebrospinal fluid of children with 454 meningitis, Antimicrob Agents Chemother, vol.23, pp.46-48, 1983.

P. H. Chandrasekar, K. V. Rolston, B. R. Smith, and J. L. Lefrock, Diffusion of ceftriaxone 456 into the cerebrospinal fluid of adults, J Antimicrob Chemother, vol.14, pp.427-430, 1984.

L. Turnier, P. Grégoire, M. Garot, D. Guimard, T. Duval et al., , p.458

E. , N. D. Asseray, and D. , CSF concentration of ceftriaxone following high-dose 459 administration: pharmacological data from two French cohorts, J Antimicrob Chemother, 2019.

M. N. Swartz, Bacterial meningitis--a view of the past 90 years, N Engl J Med, vol.461, pp.1826-1928, 2004.

J. W. Mouton, N. Punt, and A. A. Vinks, Concentration-effect relationship of ceftazidime 463 explains why the time above the MIC is 40 percent for a static effect in vivo, Agents Chemother, vol.464, pp.3449-3451, 2007.

J. W. Mouton, A. E. Muller, R. Canton, C. G. Giske, G. Kahlmeter et al., MIC-466 based dose adjustment: facts and fables, J Antimicrob Chemother, 2017.

W. Goessens, J. W. Mouton, M. T. Ten-kate, A. J. Bijl, and A. Ott, , 2007.

, Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the 469 22 intestinal flora of rats treated for an experimental pulmonary infection, J Antimicrob, vol.470, pp.507-516

, Age (years), mean

, Weight (Kg), mean [SD; min, 1 st quartile, median, 3 rd quartile, max] 74.33 [16.6; 36.6, 62, 73, 85, 146] eGFR estimated by CKD-EPI (mL/min/1.73m 2 ), mean

, Daily ceftriaxone dosage (g), mean